Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Geographic Atrophy: early-phase trial registry
13 of 28 indexed Geographic Atrophy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #577 of 28,707 conditions by registered trial count.
28 US clinical trials · 13 currently recruiting · #577 of 28,707 conditions by registered trial count
Geographic Atrophy: 28 US clinical trials tracked, 13 recruiting.
Geographic Atrophy is the subject of 28 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is Perceive Biotherapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition geographic-atrophy
OPEN 13 | RECR 46% | LATE 3 | EARLY 17 | RANK #577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Obesity, Childhood (46% recruiting · 54 trials)
Geographic Atrophy lists 13 open slots (46% of 28 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Geographic Atrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Geographic Atrophy is recruiting above its size-band peers.
13 of 28 indexed trials (46.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Geographic Atrophy trials is spread across many organizations.
Perceive Biotherapeutics accounts for 2 of 28 trials (7.1%). 23 distinct sponsors appear on at least one study for this condition label.
-
Typical Geographic Atrophy enrolment sits around 125 participants.
Median target enrolment is 125 among the 28 trials that report a genuine target (sentinel values excluded). 13 of those (46.4%) plan for fewer than 100 participants.
-
Geographic Atrophy research is mostly interventional.
21 interventional and 7 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
28 total, page 1 of 1
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Astellas Pharma Global Development
NCT06779773
High Resolution Retinal Imaging
University of Pennsylvania
NCT01866371
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Janssen Research & Development
NCT06635148
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Hoffmann-La Roche
NCT06961370
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
VisionCare
NCT05438732
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Sanofi
NCT07215234
SGLT2 Inhibitors in Geographic Atrophy
Washington University School of Medicine
NCT07174687
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
AbbVie
NCT07160179
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
Genentech
NCT05626114
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Perceive Biotherapeutics
NCT06087458
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
Nanoscope Therapeutics
NCT06805474
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
Regenerative Patch Technologies
NCT06557460
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
National Eye Institute (NEI)
NCT04339764
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)
Annexon
NCT06510816
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
Belite Bio
NCT05949593
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Apellis Pharmaceuticals
NCT06161584
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
Complement Therapeutics
NCT05797896
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
Boehringer Ingelheim
NCT06722157
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
Boehringer Ingelheim
NCT06769048
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
Ocugen
NCT06018558
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Perceive Biotherapeutics
NCT05380492
Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy
Michelle Abou-Jaoude
NCT06164587
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Apellis Pharmaceuticals
NCT03525600
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
Annexon
NCT04656561
Phase 2/3 Study of ALK-001 in Geographic Atrophy
Alkeus Pharmaceuticals
NCT03845582
A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
Genentech
NCT02288559
Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)
Carl Zeiss Meditec
NCT01272076
Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO
Optos
NCT01692938
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 9 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Geographic Atrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Geographic Atrophy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Geographic Atrophy page
28 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Geographic Atrophy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Perceive Biotherapeutics sponsors the most Geographic Atrophy trials on record, review their full trial history before evaluating a specific study. See Perceive Biotherapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Geographic Atrophy condition card totals 28 registered trials; most-linked intervention VOY-101; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.